4 research outputs found
Salts of the anti-HIV drug lamivudine with phthalic and salicylic acids
Salts of the anti-HIV drug lamivudine, with phthalic acid and salicylic acid as counterions, were investigated in this study. Neither the packing of the (lamivudine)(+)(phthalic acid)(-) ion pairs nor the conformation of the lamivudine moiety itself were similar to those found in other multicomponent molecular salts of the drug, such as hydrogen maleate and saccharinate ones, even though all three salts crystallize in the same P2(1)2(1)2(1) orthorhombic space group with similar unit cell metrics. Lamivudine salicylate assumes a different crystal structure to those of the hydrogen maleate and saccharinate salts, crystallizing in the P2(1) monoclinic space group as a monohydrate whose (lamivudine)(+)(salicylic acid)(-) ion pair is assembled through two hydrogen bonds with cytosine as a dual donor to both oxygens of the carboxylate, such as in the pairing of lamivudine with a phthalic acid counterion. In lamivudine salicylate monohydrate, the drug conformation is related to the hydrogen maleate and saccharinate salts. However, such a conformational similarity is not related to the intermolecular interaction patterns. Lamivudine and water molecules alternate into helical chains in the salicylate salt monohydrate.Brazilian Research Council CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)Brazilian Research Council CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [472623/2011-7 - Universal 14/2011
Toward Novel Solid-State Forms of the Anti-HIV Drug Efavirenz: From Low Screening Success to Cocrystals Engineering Strategies and Discovery of a New Polymorph
Efavirenz
is a first-line anti-HIV drug largely used as a non-nucleoside
reverse transcriptase inhibitor as part of antiretroviral therapies.
However, there are few reports on its solid-state structures and behaviors.
Besides that, crystal engineering strategies have not been well-exploited
for this drug and screening methods have been low promising as a source
of new solid forms. To the best of our knowledge, only two efavirenz
cocrystals have been reported thus far. On the basis of one of the
two known cocrystals, namely, that with 4,4′-bipyridine, here
we have used a rational approach for coformer selection and prediction
of structurally defined multicomponent molecular crystals. Two 4,4′-bipyridine-like
coformers, whose heterocycles are spaced by either an ethylene or
an ethane moiety, were cocrystallized together with efavirenz into
solid-state forms isostructural with respect to that of the drug cocrystal
with the antecedent coformer. The formation of a three-molecule supramolecular
entity based mainly on the NH hydrogen bonding donation from two efavirenz
molecules to both pyridyl nitrogens of each coformer unit was kept
in the three efavirenz cocrystals. Nevertheless, the introduction
of the spacer groups in the coformers has altered the pattern of weak
nonclassical hydrogen bonds of the type C–H···O
and was also related to the formation of a π–π
stacking interaction between pyridyl rings of the ethane-spaced coformer.
In addition, a polymorphic form of the drug with only one molecule
in the asymmetry unit of a <i>C</i>-centered monoclinic
lattice is reported for the first time here. It resembles a known
orthorhombic form also with <i>Z</i>′ = 1 in terms
of conformation and assembly of helical hydrogen-bonded catemers,
but their organization is unlike
Continuous Preparation of 1:1 Haloperidol–Maleic Acid Salt by a Novel Solvent-Free Method Using a Twin Screw Melt Extruder
Salts
are generally prepared by acid–base reaction in relatively
large volumes of organic solvents, followed by crystallization. In
this study, the potential for preparing a pharmaceutical salt between
haloperidol and maleic acid by a novel solvent-free method using a
twin-screw melt extruder was investigated. The pH–solubility
relationship between haloperidol and maleic acid in aqueous medium
was first determined, which demonstrated that 1:1 salt formation between
them was feasible (p<i>H</i><sub>max</sub> 4.8; salt solubility
4.7 mg/mL). Extrusion of a 1:1 mixture of haloperidol and maleic acid
at the extruder barrel temperature of 60 °C resulted in the formation
of a highly crystalline salt. The effects of operating temperature
and screw configuration on salt formation were also investigated,
and those two were identified as key processing parameters. Salts
were also prepared by solution crystallization from ethyl acetate,
liquid-assisted grinding, and heat-assisted grinding and compared
with those obtained by melt extrusion by using DSC, PXRD, TGA, and
optical microscopy. While similar salts were obtained by all methods,
both melt extrusion and solution crystallization yielded highly crystalline
materials with identical enthalpies of melting. During the pH-solubility
study, a salt hydrate form was also identified, which, upon heating,
converted to anhydrate similar to that obtained by other methods.
There were previous reports of the formation of cocrystals, but not
salts, by melt extrusion. <sup>1</sup>H NMR and single-crystal X-ray
diffraction confirmed that a salt was indeed formed in the present
study. The haloperidol–maleic acid salt obtained was nonhygroscopic
in the moisture sorption study and converted to the hydrate form only
upon mixing with water. Thus, we are reporting for the first time
a relatively simple and solvent-free twin-screw melt extrusion method
for the preparation of a pharmaceutical salt that provides material
comparable to that obtained by solution crystallization and is amenable
to continuous manufacturing and easy scale up